Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trialsGeert D’Haens, Marc Ferrante, Tadakazu Hisamatsu et al.|The Lancet|2022Cited by 383
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trialMarc Ferrante, Geert D’Haens, Remo Panaccione et al.|The Lancet|2022Cited by 312
Expediting Drug Development for Pediatric Inflammatory Bowel DiseaseAndrew E. Mulberg, Harland S. Winter, Athos Bousvaros et al.|Journal of Pediatric Gastroenterology and Nutrition|2017Cited by 1
DOP008 Safety of adalimumab in children and adolescents with moderate-to-severe Crohn’s disease: interim results of the CAPE registryDan Turner, Frank M. Ruemmele, Sibylle Koletzko et al.|Journal of Crohn s and Colitis|2018Cited by 0